When the proliferation of activated B cells and the transformed B cells were compared in vitro, the tumor cells were approximately 10-fold more sensitive to L-744,832 treatment than naïve B lymphocytes stimulated with antigen receptor and CD40 antibodies (Figure 1). The gene discussed is CD40; the disease is neoplasm.